Search
SOLACI Congress
HomePharmacologyOther

Other

View Category

Chronic Ischemic cardiopathy

Medical Therapy Optimization Achieved Prior Clinical Trial

12 weeks prior the ORBITA randomization, medical therapy optimization of all antianginal medication was achieved.   Most importantly, optimization...
solaci -
Learn More
Chronic Ischemic cardiopathy

Regression of High-Risk Plaque with Lifestyle Changes

Diet and lifestyle intervention in addition to optimal medical therapy can slow down plaque building and even...
solaci -
Learn More
Information for Patients

Might Alcohol Consumption Reduce Stroke?

A J shaped curve illustrating the link between alcohol consumption and ischemic stroke has been reported, suggesting...
solaci -
Learn More
Chronic Ischemic cardiopathy

Reducing Chronic Inflammation in Atherosclerosis with an Old Drug

Inflammation plays a crucial role in atherosclerosis progression. Recently, the COLCOT study has shown the benefits of...
solaci -
Learn More
Other

Latest News on AHA/ACC Primary Prevention Guidelines

Most cardiovascular diseases and mortality come down to 4 years of unhealthy habits (smoking, poor diet, obesity...
solaci -
Learn More
Acute coronary syndromes

Pleiotropic Effect of Metoprolol: Different From other B-blockers

The clinical practice guidelines recommend the early use of endovenous B-blockers in patients undergoing acute myocardial MI,...
solaci -
Learn More
Other

Saturated Fats: Dietary Angels or Demons?

In order to reduce cardiovascular events, dietary guidelines recommend restricting saturated fatty acids—without taking into account differences...
solaci -
Learn More
Chronic Ischemic cardiopathy

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy